150 S. Saunders Road
About Horizon Therapeutics
Horizon is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. Our pipeline is purposeful: we apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives. For more information on how we go to incredible lengths to impact lives, please visit www.horizontherapeutics.com.
Stock Exchange: NASDAQ
Stock symbol: HZNP
At Horizon, we work to define ourselves by a different set of numbers - the number of patients helped, lives changed, lives saved. The outcomes we attain – and the lengths we go to achieve them – reflect a commitment to the communities we serve and our company ideals. In this video, hear from our employees on why working at Horizon is personal – because we know that by living up to our own potential, we are helping others live up to theirs.
377 articles with Horizon Therapeutics
Horizon Therapeutics plc Initiates PROTECT Trial Evaluating KRYSTEXXA® (pegloticase injection) to Improve Management of Uncontrolled Gout for Adults with a Kidney Transplant
Horizon Therapeutics plc (Nasdaq: HZNP) today announced it has initiated an open-label clinical trial evaluating the use of KRYSTEXXA® (pegloticase injection) in adults with chronic gout refractory to conventional therapies – also known as uncontrolled gout – who have undergone a kidney transplant to demonstrate that KRYSTEXXA may provide effective disease control without burdening the kidneys.
FORTUNE and Great Place to Work® Name Horizon Therapeutics plc to Best Small & Medium Workplaces List for Fourth Consecutive Year
Horizon ranked eighth out of 100 other medium sized companies.
New Data from Teprotumumab Phase 3 OPTIC Study Shows Significantly Reduced Double Vision and Improved Quality of Life for People with Active Thyroid Eye Disease
Horizon Therapeutics plc (Nasdaq: HZNP) today announced new data from the Phase 3 OPTIC confirmatory clinical trial showing that teprotumumab provided significant benefit on several devastating effects of active thyroid eye disease (TED) compared with placebo, including diplopia (double vision), quality of life (QoL) and clinical activity score (CAS).
Horizon Therapeutics plc to Release Third-Quarter 2019 Financial Results and Host Webcast on Nov. 6, 2019
Horizon Therapeutics plc (Nasdaq: HZNP) announced today that its third-quarter 2019 financial results will be released on Wednesday, Nov. 6, 2019. Following the announcement, Horizon's management will host a live webcast at 8 a.m. Eastern Time to review the Company's financial and operating results.
New Data Insights from the Phase 3 Teprotumumab Trial (OPTIC) to be Presented at the American Society of Ophthalmic Plastic and Reconstructive Surgery (ASOPRS) Scientific Symposium
Additional results from the Phase 3 confirmatory clinical trial (OPTIC) of teprotumumab, an investigational medicine being developed by Horizon Therapeutics plc, will be presented at the American Society of Ophthalmic Plastic and Reconstructive Surgery (ASOPRS) 50th Anniversary 2019 Fall Scientific Symposium in San Francisco on Oct. 11.
Horizon Therapeutics plc Named One of the Best Adoption-Friendly Workplaces by the Dave Thomas Foundation for Adoption
The list recognizes organizations with the most robust adoption benefit programs, comparing financial reimbursement and paid leave offered to employees who adopt, based on a survey of organizations across the United States.
Horizon Therapeutics plc Announces the FDA has Granted Priority Review of the Teprotumumab Biologics License Application (BLA) for the Treatment of Active Thyroid Eye Disease (TED)
If Approved, Teprotumumab Would be the First FDA-Approved Medicine for this Vision-Threatening Disease
Horizon Therapeutics plc to Participate in the Morgan Stanley 17th Annual Global Healthcare Conference
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the company will participate in the following conference in September:
Horizon Therapeutics plc Reports Strong Second-Quarter 2019 Results;Increases Full‐Year 2019 Net Sales and Adjusted EBITDA Guidance
Second-Quarter 2019 Net Sales of $320.6 Million Increased 6 Percent; Second-Quarter 2019 GAAP Net Loss of $5.1 Million; Adjusted EBITDA of $124.1 Million
Dr. Mahony brings more than three decades of broad cross-functional and global experience to the board.
Horizon Therapeutics plc (Nasdaq: HZNP) today announced the availability of an expanded access program for its investigational medicine teprotumumab.
Horizon Therapeutics plc Wins International CSR Excellence Award for Partnership with Perspectives Math and Science Academy
Since 2016, Horizon’s partnership with MSA has focused on three areas of giving: infrastructure, programming and employee engagement.
Horizon Therapeutics plc Announces U.S. FDA Acceptance of its New Drug Application to Make PROCYSBI® (Cysteamine Bitartrate) Available as Oral Granules in Packets
The FDA is expected to make a decision on the approval of the proposed new dosage form of granules in packets in 2020.
Great Place to Work is an organization whose goal it is to assure that all people in the U.S. have a great place to work by 2030. One category for certified companies is Biotechnology & Pharmaceuticals, which listed 36 companies. BioSpace organized these 36 companies into its BioSpace Hotbed Regi...
Horizon Therapeutics plc to Release Second-Quarter 2019 Financial Results and Host Webcast on Aug. 7, 2019
Following the announcement, Horizon's management will host a live webcast at 8 a.m. Eastern Time to review the Company's financial and operating results.
Horizon Therapeutics plc (Nasdaq: HZNP) (“Horizon”) today announced that Horizon Pharma USA, Inc., its wholly-owned subsidiary, has priced its offering of $600 million aggregate principal amount of 5.5% senior notes due 2027.
Horizon Therapeutics plc Submits Teprotumumab Biologics License Application (BLA) for the Treatment of Active Thyroid Eye Disease (TED)
Horizon Therapeutics plc announced that it has submitted a Biologics License Application to the U.S. Food and Drug Administration for its investigational medicine teprotumumab for the treatment of active thyroid eye disease.
Horizon Therapeutics plc (Nasdaq: HZNP) today announced that Horizon Pharma USA, Inc., its wholly-owned subsidiary, intends, subject to market and other considerations, to offer $500 million aggregate principal amount of senior notes due 2027.
6/27/2019Biotech and pharma companies from across the globe share pipeline and business updates.
Horizon Therapeutics plc Initiates MIRROR Randomized Controlled Trial Evaluating KRYSTEXXA® (pegloticase injection) in Combination with Methotrexate to Increase Response Rates and Duration of Therapy
Horizon Therapeutics plc (Nasdaq: HZNP) today announced the initiation of a clinical trial evaluating KRYSTEXXA® (pegloticase injection) in combination with methotrexate as a strategy to increase the durability of response for patients living with chronic gout refractory to conventional therapies – also known as uncontrolled gout.